@article{chon_sakthikumar_tang_hamilton_vaughan_smith_sommer_robat_manley_mullin_et al._2023, title={Novel genomic prognostic biomarkers for dogs with cancer}, volume={10}, ISSN={["1939-1676"]}, DOI={10.1111/jvim.16893}, abstractNote={Abstract}, journal={JOURNAL OF VETERINARY INTERNAL MEDICINE}, author={Chon, Esther and Sakthikumar, Sharadha and Tang, Min and Hamilton, Matthew J. and Vaughan, Andrew and Smith, Ashley and Sommer, Breann and Robat, Cecilia and Manley, Christina and Mullin, Christine and et al.}, year={2023}, month={Oct} }
 @article{medland_marks_intile_2022, title={Discharge summaries provided to owners of pets newly diagnosed with cancer exceed recommended readability levels}, volume={260}, ISSN={["1943-569X"]}, DOI={10.2460/javma.21.09.0410}, abstractNote={Abstract}, number={6}, journal={JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION}, author={Medland, Julia E. and Marks, Steven L. and Intile, Joanne L.}, year={2022}, month={Mar}, pages={657–661} }
 @article{berlato_bulman-fleming_clifford_garrett_intile_jones_kamstock_liptak_pavuk_powell_et al._2021, title={Value, Limitations, and Recommendations for Grading of Canine Cutaneous Mast Cell Tumors: A Consensus of the Oncology-Pathology Working Group}, volume={4}, ISSN={["1544-2217"]}, DOI={10.1177/03009858211009785}, abstractNote={ One of the primary objectives of the Oncology Pathology Working Group (OPWG), a joint initiative of the Veterinary Cancer Society and the American College of Veterinary Pathologists, is for oncologists and pathologists to collaboratively generate consensus documents to standardize aspects and provide guidelines for oncologic pathology. Consensus is established through review of relevant peer-reviewed literature relative to a subgroup’s particular focus. In this article, the authors provide a critical review of the current literature for grading of canine cutaneous mast cell tumors, suggest guidelines for reporting, and provide recommendations for its clinical interpretation. The article mainly focuses on histologic grading, but relevant information on mitotic count and cytological grading are also discussed. This document represents the opinions of the working group and the authors but does not constitute a formal endorsement by the American College of Veterinary Pathologists or the Veterinary Cancer Society. }, journal={VETERINARY PATHOLOGY}, author={Berlato, Davide and Bulman-Fleming, Julie and Clifford, Craig A. and Garrett, Laura and Intile, Joanne and Jones, Pamela and Kamstock, Debra A. and Liptak, Julius M. and Pavuk, Alana and Powell, Roger and et al.}, year={2021}, month={Apr} }
 @article{fogle_intile_sheats_2021, title={Veterinary Clinical Ethics and Patient Care Dilemmas}, volume={51}, ISSN={["1878-1306"]}, DOI={10.1016/j.cvsm.2021.05.003}, abstractNote={Veterinary ethical dilemmas are common, complex, and unavoidable. Creating a transparent and deliberate approach to ethical issues empowers the entire veterinary team and reduces stress associated with these dilemmas. This article discusses ethical considerations and principles and propose use of the 4Es model and core communication skills to address ethical dilemmas in veterinary practice. It reviews literature defining ethical issues in practice and provides case examples to show the application of our proposed methods. The goal is to provide veterinary professionals with an approach they can use to frame and address their own ethical decisions.}, number={5}, journal={VETERINARY CLINICS OF NORTH AMERICA-SMALL ANIMAL PRACTICE}, author={Fogle, Callie and Intile, Joanne and Sheats, Mary Katherine}, year={2021}, month={Sep}, pages={1079–1097} }
 @inbook{intile_2019, edition={4th}, title={Anal Sac}, booktitle={Clinical Veterinary Advisor: Dogs and Cats}, publisher={Elsevier}, author={Intile, J.L.}, editor={Cote, E.Editor}, year={2019} }
 @article{intile_rassnick_al-sarraf_chretin_2019, title={Evaluation of the Tolerability of Combination Chemotherapy with Mitoxantrone and Dacarbazine in Dogs with Lymphoma}, volume={55}, ISSN={["1547-3317"]}, DOI={10.5326/JAAHA-MS-6878}, abstractNote={ABSTRACT}, number={2}, journal={JOURNAL OF THE AMERICAN ANIMAL HOSPITAL ASSOCIATION}, author={Intile, Joanne L. and Rassnick, Kenneth M. and Al-Sarraf, Renee and Chretin, John D.}, year={2019}, pages={101–109} }
 @inbook{intile_2019, edition={4th}, title={Lymphoma, Rescue Therapy}, booktitle={Clinical Veterinary Advisor: Dogs and Cats}, publisher={Elsevier}, author={Intile, J.L.}, editor={Cote, E.Editor}, year={2019} }
 @inbook{intile_2019, edition={4th}, title={Perianal}, booktitle={Clinical Veterinary Advisor: Dogs and Cats}, author={Intile, J.L.}, editor={Cote, E.Editor}, year={2019} }
 @misc{thamm_avery_berlato_bulman-fleming_clifford_hershey_intile_jones_kamstock_liptak_et al._2019, title={Prognostic and predictive significance of KIT protein expression and c-kit gene mutation in canine cutaneous mast cell tumours: A consensus of the Oncology-Pathology Working Group}, volume={17}, ISSN={["1476-5829"]}, DOI={10.1111/vco.12518}, abstractNote={Abstract}, number={4}, journal={VETERINARY AND COMPARATIVE ONCOLOGY}, author={Thamm, Douglas H. and Avery, Anne C. and Berlato, Davide and Bulman-Fleming, Julie and Clifford, Craig A. and Hershey, A. Elizabeth and Intile, Joanne L. and Jones, Pamela D. and Kamstock, Debra A. and Liptak, Julius M. and et al.}, year={2019}, month={Dec}, pages={451–455} }
 @article{epperly_hume_moirano_stokol_intile_erb_scrivani_2018, title={Dogs with acute myeloid leukemia or lymphoid neoplasms (large cell lymphoma or acute lymphoblastic leukemia) may have indistinguishable mediastinal masses on radiographs}, volume={59}, ISSN={["1740-8261"]}, DOI={10.1111/vru.12622}, abstractNote={Abstract}, number={5}, journal={VETERINARY RADIOLOGY & ULTRASOUND}, author={Epperly, Erin and Hume, Kelly R. and Moirano, Steven and Stokol, Tracy and Intile, Joanne and Erb, Hollis N. and Scrivani, Peter V.}, year={2018}, pages={507–515} }
 @article{rassnick_bailey_malone_flory_kiselow_intile_2014, title={Tolerability of Lomustine in Combination with Cyclophosphamide in Dogs with Lymphoma}, volume={50}, ISSN={0587-2871 1547-3317}, url={http://dx.doi.org/10.5326/jaaha-ms-6020}, DOI={10.5326/jaaha-ms-6020}, abstractNote={This retrospective study describes toxicity associated with a protocol of lomustine (CCNU) and cyclophosphamide (CTX) in dogs with lymphoma. CCNU was administered per os (PO) at a targeted dosage of 60 mg/m2 body surface area on day 0, CTX was administered PO at a targeted dosage of 250 mg/m2 divided over days 0 through 4, and all dogs received prophylactic antibiotics. Ninety treatments were given to the 57 dogs included in the study. Neutropenia was the principal toxic effect, and the overall frequency of grade 4 neutropenia after the first treatment of CCNU/CTX was 30% (95% confidence interval, 19–43%). The mean body weight of dogs with grade 4 neutropenia (19.7 kg ± 13.4 kg) was significantly less than the mean body weight of dogs that did not develop grade 4 neutropenia (31.7 kg ± 12.4 kg; P = .005). One dog (3%) developed hematologic changes suggestive of hepatotoxicity. No dogs had evidence of either renal toxicity or hemorrhagic cystitis. Adverse gastrointestinal effects were uncommon. On the basis of the findings reported herein, a dose of 60 mg/m2 of CCNU combined with 250 mg/m2 of CTX (divided over 5 days) q 4 wk is tolerable in tumor-bearing dogs.}, number={3}, journal={Journal of the American Animal Hospital Association}, publisher={American Animal Hospital Association}, author={Rassnick, Kenneth M. and Bailey, Dennis B. and Malone, Erin K. and Flory, Andrea B. and Kiselow, Michael A. and Intile, Joanne L.}, year={2014}, month={May}, pages={167–173} }
 @article{rassnick_bailey_russell_flory_kiselow_intile_malone_balkman_barnard_2010, title={A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours}, volume={8}, ISSN={1476-5810 1476-5829}, url={http://dx.doi.org/10.1111/j.1476-5829.2010.00217.x}, DOI={10.1111/j.1476-5829.2010.00217.x}, abstractNote={Safety and efficacy of a protocol of alternating 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; 70 mg m(-2)) and vinblastine (3.5 mg m(-2)), and prednisone (1-2 mg kg(-1); CVP) in dogs with mast cell tumours (MCT) were evaluated. A total of 17 dogs had nonresectable MCTs and 35 received CVP as adjunctive treatment to locoregional control of metastatic MCTs or grade III MCTs. Neutropenia with fever occurred in 8% of dogs after treatment with vinblastine and in 2% after treatment with CCNU. Persistent elevation of serum alanine transaminase, suggestive of hepatotoxicity, occurred in 9% of the dogs. Response rate in dogs with nonresectable MCTs was 65%; five achieved a complete response (median, 141 days) and six achieved a partial response (median, 66 days). Overall median progression-free survival (PFS) time in dogs treated in the adjuvant setting was 489 days. Dogs with grade III MCTs had shorter PFS compared with dogs with metastatic grade II MCTs (190 days versus 954 days; P < 0.001). Phase III studies are needed to provide reliable information about the comparative efficacy of this protocol.}, number={2}, journal={Veterinary and Comparative Oncology}, publisher={Wiley}, author={Rassnick, K. M. and Bailey, D. B. and Russell, D. S. and Flory, A. B. and Kiselow, M. A. and Intile, J. L. and Malone, E. K. and Balkman, C. E. and Barnard, S. M.}, year={2010}, month={Jun}, pages={138–152} }
 @article{rassnick_bailey_malone_intile_kiselow_flory_barlow_balkman_barnard_waite_et al._2010, title={Comparison between l-CHOP and an l-CHOP protocol with interposed treatments of CCNU and MOPP (l-CHOP-CCNU-MOPP) for lymphoma in dogs}, volume={8}, ISSN={1476-5810}, url={http://dx.doi.org/10.1111/j.1476-5829.2010.00224.x}, DOI={10.1111/j.1476-5829.2010.00224.x}, abstractNote={An L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) was evaluated in 66 dogs with stages III-V lymphoma. Results were compared with a historical group of 71 dogs treated with an L-CHOP protocol. Complete remission (CR) rates (85 and 80%, respectively) did not differ significantly between protocols (P = 0.48). First CR duration for dogs treated with L-CHOP-CCNU-MOPP was significantly longer: median, 317 days; 2-year CR rate, 35% versus median, 298 days; 2-year CR rate, 13%, P = 0.05). For the L-CHOP-CCNU-MOPP protocol, dogs in substage-b had a 4.3 times greater hazard of having a relapse than dogs in substage-a (P = 0.002). Frequency of adverse chemotherapy-associated gastrointestinal effects did not differ between protocols (P = 0.77). Neutropenia (primarily after CCNU) occurred more frequently in dogs treated with L-CHOP-CCNU-MOPP (P < 0.001). In summary, the L-CHOP-CCNU-MOPP protocol showed an improved duration of first CR as compared with an L-CHOP protocol, but the relevance of this finding might be subject to clinical judgement.}, number={4}, journal={Veterinary and Comparative Oncology}, publisher={Wiley}, author={Rassnick, K. M. and Bailey, D. B. and Malone, E. K. and Intile, J. L. and Kiselow, M. A. and Flory, A. B. and Barlow, L. L. and Balkman, C. E. and Barnard, S. M. and Waite, A. H. and et al.}, year={2010}, month={Nov}, pages={243–253} }
 @article{rassnick_moore_russell_northrup_kristal_bailey_flory_kiselow_intile_2010, title={Phase II, Open-Label Trial of Single-Agent CCNU in Dogs with Previously Untreated Histiocytic Sarcoma}, volume={24}, ISSN={0891-6640}, url={http://dx.doi.org/10.1111/j.1939-1676.2010.0588.x}, DOI={10.1111/j.1939-1676.2010.0588.x}, abstractNote={BACKGROUND
Histiocytic sarcoma (HS) is an aggressive neoplasm in dogs, and in most instances, the disease is localized, but not amenable to surgical removal, or is disseminated. Affected patients usually die within 6 months. There have been no prospective studies to determine efficacy of single-agent chemotherapy in dogs with HS.


HYPOTHESIS
Single-agent CCNU [1-(2-chloroethyl)3-cyclohexyl-1-nitrosourea; lomustine] has antitumor activity against HS in dogs.


ANIMALS
Twenty-one dogs with histologically confirmed, nonresectable localized or disseminated HS.


METHODS
Prospective, open-label phase II clinical trial in which dogs with previously untreated HS were uniformly treated with CCNU as a single oral dosage of 90 mg/m2 every 4 weeks. The primary outcome measure was reduction in tumor size.


RESULTS
Fourteen dogs with disseminated HS and 7 with localized HS were enrolled between 1999 and 2008. Overall response rate was 29% (95% confidence interval [CI], 14–50%) for a median of 96 days (95% CI, 55–137 days). Three dogs (1 disseminated, 2 localized) had complete responses lasting for 54–269 days and 3 dogs (2 disseminated, 1 localized) had partial responses lasting for 78–112 days.


CONCLUSIONS AND CLINICAL IMPORTANCE
CCNU, when used as a single agent, has activity against HS in dogs. Evaluation of CCNU postoperatively for dogs with resectable localized HS and as part of combination therapy for tumors that are nonresectable or disseminated should be considered.}, number={6}, journal={Journal of Veterinary Internal Medicine}, publisher={Wiley}, author={Rassnick, K.M. and Moore, A.S. and Russell, D.S. and Northrup, N.C. and Kristal, O. and Bailey, D.B. and Flory, A.B. and Kiselow, M.A. and Intile, J.L.}, year={2010}, month={Sep}, pages={1528–1531} }
 @article{intile_rassnick_bailey_al-sarraf_chretin_balkman_flory_kiselow_wakshlag_2009, title={Evaluation of dexamethasone as a chemoprotectant for CCNU-induced bone marrow suppression in dogs}, volume={7}, ISSN={1476-5810 1476-5829}, url={http://dx.doi.org/10.1111/j.1476-5829.2008.00175.x}, DOI={10.1111/j.1476-5829.2008.00175.x}, abstractNote={Abstract}, number={1}, journal={Veterinary and Comparative Oncology}, publisher={Wiley}, author={Intile, J. L. and Rassnick, K. M. and Bailey, D. B. and Al-Sarraf, R. and Chretin, J. D. and Balkman, C. E. and Flory, A. B. and Kiselow, M. A. and Wakshlag, J. J.}, year={2009}, month={Mar}, pages={69–77} }
 @article{rassnick_bailey_flory_balkman_kiselow_intile_autio_2008, title={Efficacy of Vinblastine for Treatment of Canine Mast Cell Tumors}, volume={22}, ISSN={0891-6640 1939-1676}, url={http://dx.doi.org/10.1111/j.1939-1676.2008.0195.x}, DOI={10.1111/j.1939-1676.2008.0195.x}, abstractNote={Background:  The optimal dosage and clinical efficacy of vinblastine (VBL) for treatment of mast cell tumors (MCTs) in dogs has not been established.}, number={6}, journal={Journal of Veterinary Internal Medicine}, publisher={Wiley}, author={Rassnick, K.M. and Bailey, D.B. and Flory, A.B. and Balkman, C.E. and Kiselow, M.A. and Intile, J.L. and Autio, K.}, year={2008}, month={Nov}, pages={1390–1396} }
 @article{nitabach_llamas_araneda_intile_thompson_zhou_holmes_2001, title={A mechanism for combinatorial regulation of electrical activity: Potassium channel subunits capable of functioning as Src homology 3-dependent adaptors}, volume={98}, ISSN={0027-8424 1091-6490}, url={http://dx.doi.org/10.1073/pnas.98.2.705}, DOI={10.1073/pnas.031446198}, number={2}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Nitabach, M. N. and Llamas, D. A. and Araneda, R. C. and Intile, J. L. and Thompson, I. J. and Zhou, Y. I. and Holmes, T. C.}, year={2001}, month={Jan}, pages={705–710} }